Elan Corporation, plc (ELN)
-NYSE 15.68 
0.06(0.38%) 3:21PM EDT - Nasdaq Real Time Price
| Prev Close: | 15.74 |
|---|
| Open: | 15.71 |
|---|
| Bid: | 15.69 x 13600 |
|---|
| Ask: | 15.70 x 6200 |
|---|
| 1y Target Est: | 14.04 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 15.65 - 15.76 |
|---|
| 52wk Range: | 9.37 - 15.92 |
|---|
| Volume: | 6,050,528 |
|---|
| Avg Vol (3m): | 9,564,900 |
|---|
| Market Cap: | 8.02B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Update on Alkermes' PortfolioZacks(Wed 1:10PM EDT)
- InPlay: Elan has scheduled shareholder meetings for November 18 in connection with Perrigo (PRGO) proposed acquisition of ElanBriefing.com(Mon, Sep 30)
- Elan Announces Dates of Shareholder Meetings in Connection with Scheme of ArrangementBusiness Wire(Mon, Sep 30)
- Santarus (SNTS) in Focus: Stock Advances 6.2%Zacks(Fri, Sep 27)
- Good News for Perrigo's Generic UnitZacks(Tue, Sep 24)
- Strength Seen in PTC Therapeutics (PTCT): Stock Surges 25.7%Zacks(Tue, Sep 24)
- Still Neutral on PerrigoZacks(Thu, Sep 19)
- Is Clovis Oncology a Wolf in Sheep's Clothing?at Motley Fool(Wed, Sep 18)
- FDA Designation for Forest AntibioticZacks(Tue, Sep 17)
- Big Pharma Provides an Attractive Return Profile Trading at 12.5x, 3% Dividend Yield and 5% Organic Growth: Which Names Should You Buy?Wall Street Transcript(Mon, Sep 16)
- FDA Develops New Treatment of Biosimilars: a Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & CompanyWall Street Transcript(Fri, Sep 13)
- Theravance Gets Big Win for New COPD Drugat Motley Fool(Tue, Sep 10)
- Investors Should Brace for a Busy Week From the Biotech Sectorat Motley Fool(Sat, Sep 7)
- Pharma's Holy Grail: The next Alzheimer's drugat CNBC(Thu, Sep 5)
- U.S. Pharma Prescribes A Dose Of Irish Tax Dealsat Forbes(Thu, Sep 5)
Key Statistics
| Forward P/E (1 yr): | 58.15 |
|---|
| P/S (ttm): | 142.02 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 4.44 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 0.02 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | 1.61 |
|---|
Business Summary
Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple ...
View More